Please assess the completion status of the following clinical trial:

Trial Title: Compliance With Antidepressant Medication in Treatment of Functional Dyspepsia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* met the ROME III criteria for FD;~* education level no lower than high school;~* Hospital Anxiety and Depression Scale (HADS) score \> 8 respectively;~* absence of abnormalities in physical examination, laboratory tests (including a routine blood test, blood glucose, and liver function examination), abdominal ultrasonography and upper GI endoscopy within 6 months;~* absence of H. pylori infection~Exclusion Criteria:~* known allergy to omeprazole, flupenthixol or melitracen;~* any evidence of organic digestive diseases;~* reflux-related symptoms only (e.g., retrosternal pain, burning and regurgitation) or predominantly reflux-related symptoms;~* severe psychological symptoms that affected life and work;~* pregnancy or breastfeeding;~* recent myocardial infarction or cardiac arrhythmias;~* previous gastric surgery;~* use of PPIs, psychoactive drugs or other drugs that might affect gastric function within 6 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Flupentixol-Melitracen(psychological and GI) + Omeprazole (Type: ACTIVE_COMPARATOR): The patients in Group 1 were told that: GI symptoms in FD are attributable to both psychological and GI mechanisms. Flupentixol-Melitracen relieves FD symptoms through both psychological and GI mechanisms.
- Flupentixol-Melitracen(psychological) + Omeprazole (Type: ACTIVE_COMPARATOR): The patients in Group 2 were told that: GI symptoms were attributable to somatization of their psychological problems; and Flupentixol-Melitracen is an antipsychotic drug and primarily acts centrally to alleviate FD symptoms by regulating the psychological condition.
- Flupentixol-Melitracen(without explanation) + Omeprazole (Type: ACTIVE_COMPARATOR): In Group 3, the patients were told only that Flupentixol-Melitrace has been proven to be effective in FD treatment and were not provided additional explanations of the relationships between their GI symptoms and their psychological condition and the reasons for the prescription of Flupentixol-Melitrace.
- proton pump inhibitor (Type: ACTIVE_COMPARATOR): Prescribe Omeprazole.

Based on this trial design, predict the completion outcome and termination type (if applicable).